JPMorgan said its survey of 28 physicians treating transthyretin amyloid cardiomyopathy, or ATTR-CM, pointed to steady uptake of BridgeBio’s drug Attruby among newly diagnosed patients and among those whose disease has progressed despite treatment with tafamidis.
The bank said doctors continue to favor stabilizer drugs such as Attruby and tafamidis over “knockdown” therapies that reduce production of the transthyretin protein.
Among physicians surveyed, about one-third said Attruby had a slight or meaningful advantage in overall clinical profile compared with tafamidis products such as Vyndaqel and Vyndamax, largely due to efficacy.
Some investors have raised concerns about competition once generic versions of tafamidis enter the market. JPMorgan said it expects that loss of exclusivity to occur in December 2028 for the tafamidis franchise developed by Pfizer, which it views as the base-case scenario.
Even after generic entry, the bank expects Attruby to lose only incremental market share in newly diagnosed patients, partly offset by higher diagnosis rates over time.
Beyond Attruby, JPMorgan said BridgeBio’s late-stage pipeline remains undervalued. The brokerage highlighted programs including infigratinib for achondroplasia, encaleret for autosomal dominant hypocalcemia and BBP-418 for limb-girdle muscular dystrophy.
source https://www.investing.com/news/stock-market-news/jpmorgan-adds-bridgebio-to-focus-list-lifts-target-to-94-4555222
